ELTX Elicio Therapeutics, Inc.

NASDAQ
$1.50

Elicio Therapeutics, Inc. (ELTX) is expected to report earnings on February 4, 2027, after the market close. The consensus earnings estimate is a loss of $0.25 per share, and the stock has had a Post-Earnings Announcement Drift (PEAD) of +7.1% since its last earnings release on November 5, 2026.

Elicio Therapeutics Beat Consensus Estimates
Thursday, November 5, 2026 · 4:01 PM ET
Earnings Date
4th Quarter, Dec 2026
Feb 4
Thursday · 4:00 PM ET
Earnings Whisper
-
vs ($0.25)
Volatility
Enter your expectations below to reveal the current volatility.
Trend Analysis
Expectation
Earnings
Price action
Signals
Score
Sentiment
Grade
Life Cycle
Call Analysis
Earnings-AVWAP $1.54

Sign in or subscribe to unlock sentiment, short interest, and technical indicators.

About Elicio Therapeutics, Inc.

Elicio Therapeutics is a privately-held clinical-stage biotechnology company. It involved in developing a pipeline of novel immunotherapies for the treatment of cancer and other diseases. Elicio Therapeutics, formerly known as Angion Biomedica Corp, is based in BOSTON.

Sector

Healthcare

Industry

Biotechnology

Charts powered in part by Lightweight Charts™ by TradingView.